Prothena Corporation PLC (NASDAQ:PRTA) – Jefferies Group lowered their Q3 2017 earnings per share (EPS) estimates for Prothena Corporation PLC in a research report issued on Tuesday. Jefferies Group analyst M. Yee now anticipates that the biotechnology company will post earnings of ($1.54) per share for the quarter, down from their previous forecast of ($1.48). Jefferies Group has a “Buy” rating and a $100.00 price objective on the stock. Jefferies Group also issued estimates for Prothena Corporation PLC’s Q4 2017 earnings at ($1.77) EPS, FY2017 earnings at ($4.80) EPS and FY2018 earnings at ($6.82) EPS.
PRTA has been the topic of several other research reports. Zacks Investment Research upgraded Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a report on Tuesday, April 18th. BidaskClub raised Prothena Corporation PLC from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 19th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $70.00 price objective on shares of Prothena Corporation PLC in a research report on Thursday, July 6th. ValuEngine raised Prothena Corporation PLC from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Finally, BTIG Research started coverage on Prothena Corporation PLC in a research report on Friday, May 19th. They issued a “buy” rating and a $80.00 price objective for the company. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Prothena Corporation PLC has an average rating of “Buy” and an average target price of $77.09.
Prothena Corporation PLC (NASDAQ PRTA) opened at 57.16 on Friday. Prothena Corporation PLC has a 52-week low of $40.58 and a 52-week high of $69.53. The stock’s 50 day moving average is $60.52 and its 200-day moving average is $54.91. The firm’s market capitalization is $2.19 billion.
Prothena Corporation PLC (NASDAQ:PRTA) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.43. The firm had revenue of $26.81 million for the quarter, compared to analysts’ expectations of $16.08 million. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 34.50%. Prothena Corporation PLC’s revenue was up 7951.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.18) earnings per share.
In related news, Director Dennis J. Selkoe sold 3,500 shares of the firm’s stock in a transaction on Friday, July 7th. The stock was sold at an average price of $58.11, for a total value of $203,385.00. Following the completion of the transaction, the director now directly owns 6,345 shares of the company’s stock, valued at $368,707.95. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Karin L. Walker sold 5,000 shares of the firm’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $64.89, for a total value of $324,450.00. Following the completion of the transaction, the insider now directly owns 5,000 shares of the company’s stock, valued at $324,450. The disclosure for this sale can be found here. 3.10% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of PRTA. Bank of Montreal Can boosted its position in shares of Prothena Corporation PLC by 6.7% in the second quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 117 shares during the period. Quantbot Technologies LP boosted its position in shares of Prothena Corporation PLC by 672.7% in the second quarter. Quantbot Technologies LP now owns 1,870 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 1,628 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Prothena Corporation PLC by 187.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,375 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 1,549 shares during the period. Ameritas Investment Partners Inc. purchased a new position in shares of Prothena Corporation PLC during the first quarter valued at approximately $167,000. Finally, Sei Investments Co. purchased a new position in shares of Prothena Corporation PLC during the second quarter valued at approximately $176,000.
Prothena Corporation PLC Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
What are top analysts saying about Prothena Corporation PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Prothena Corporation PLC and related companies.